Steven Cohen Rhythm Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 170,832 shares of RYTM stock, worth $18.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
170,832
Previous 63,842
167.59%
Holding current value
$18.3 Million
Previous $3.38 Million
219.25%
% of portfolio
0.02%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RYTM
# of Institutions
250Shares Held
63.9MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$722 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$601 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$596 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$523 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$385 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $5.97B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...